Sergio Espinosa Gil Profile
Sergio Espinosa Gil

@SergioE32429537

Followers
4
Following
17
Media
0
Statuses
11

Joined July 2019
Don't wanna be here? Send us removal request.
@JoseLizk
jose m lizcano
2 years
Happy to share our last work on MAP kinase #ERK5. We describe the #oncogenic MEK5-ERK5 pathway as a critical regulator of #cancer cell #resistance to extrinsic #apoptosis induced by death receptor ligands #TNFa, #FasL, and #TRAIL. https://t.co/tEG7ZBaIHI
7
5
41
@JoseLizk
jose m lizcano
2 years
Very proud of our *new PhD in the lab* 🙂! Congrats to *Dr. Sergio Espinosa* @SergioE32429537 for an excellent presentation and scientific discussion👌. Big thanks to the PhD Committee Dr Ana Cuenda @CuendaAna, Dr Joan Seoane @seoanelab and Dr Martin Villalba!
4
7
42
@VHIR_
Vall d'Hebron Institut de Recerca
3 years
En los últimos años, el papel de la proteína #ERK5 en #cáncer está siendo especialmente investigado. #VallHebron ha organizado el primer congreso mundial para establecer las bases de colaboración entre expertos internacionales en este campo. Lee más: https://t.co/VoutWQM39K
0
4
9
@JoseLizk
jose m lizcano
3 years
Happy to share our latest work on #ERK5 in #endometrial #cancer, where we describe MAP kinase ERK5 and NF-kB pathways as new targets to tackle EC👇 The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival
Tweet card summary image
biorxiv.org
Endometrial cancer (EC) is the most common type of gynaecologic cancer in women of developed countries. Despite surgery combined with chemo-/radiotherapy regimens, overall survival of patients with...
1
3
9
@SergioE32429537
Sergio Espinosa Gil
4 years
compro 1 entrada de razz dia 13 d'abril #razz #razzmatazz
1
0
0
@UABBarcelona
Universitat Autònoma de Barcelona
5 years
Un equip de #recercaUAB de l’@INC_UAB identifica una nova via per atacar les cèl·lules tumorals ➡ https://t.co/5GxdBPP3mY #UAB @IQAC_CSIC @JoseLizk @AbilityPharma @PRUAB @ICOnoticies @unicomplutense @VHIR_ @VHIO @idibell_cat
3
22
84
@CDomenech_APh
Carles Domenech APh
5 years
"AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical autophagy inducer in cancer cells, in Autophagy" https://t.co/TzIScQp54Z by @CDomenech_APh on @LinkedIn
linkedin.com
BARCELONA – June 9, 2020 - The biopharmaceutical company Ability Pharmaceuticals SL announced today that the full description of the mechanism of action of ABTL0812 has been published in the presti...
0
6
15
@JoseLizk
jose m lizcano
5 years
Check our last work on dihydroceramides causing ER stress-mediated cytotoxic autophagy in cancer cells, published in Autophagy. Mechanism revealed using the new antitumor drug ABTL0812, currently in phase II clinical trial lead by @AbilityPharma 👇 https://t.co/V9c0IwaogE
4
17
39
@DjMaRiiO
DjMaRiiO
6 years
🟢SORTEO 72.000 FIFA POINTS para los TOTS🟢 -Participas si me sigues y das RT a este tuit, fácil y rápido. 6 ganadores, mucha suerte papus ♥️
2K
55K
33K
@JoseLizk
jose m lizcano
6 years
Sergio, PhD student in our lab (@JoseLizk) won the prize to best SEBBM poster: ERK5 mediates EGF-induced cancer cell proliferation @42congresoSEBBM.
3
8
37